PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement

被引：0

作者：

Abou-Alfa, G. ^{[1
]}

Borbath, I. ^{[2
]}

Goyal, L. ^{[3
]}

Lamarca, A. ^{[4
]}

Macarulla, T. ^{[5
]}

Oh, D. ^{[6
]}

Roychowdhury, S. ^{[7
]}

Sadeghi, S. ^{[8
]}

Shroff, R. ^{[9
]}

Soto, J. ^{[10
]}

Pedrioli, G. ^{[11
]}

Fumagalli, L. ^{[11
]}

Dambkowski, C. ^{[10
]}

Javle, M. ^{[12
]}

机构：

[1] Cornell Univ, Mem Sloan Kettering Canc Ctr, Weill Med Coll, New York, NY 10021 USA

[2] Clin Univ St Luc, Brussels, Belgium

[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[4] Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England

[5] Hosp Valle De Hebron, Barcelona, Spain

[6] Seoul Natl Univ, Coll Med, Seoul, South Korea

[7] Ohio State Comprehens Canc Ctr, Columbus, OH USA

[8] Univ Calif Los Angeles, David Geffen Sch Med, Santa Monica, CA USA

[9] Univ Arizona, Ctr Canc, Tucson, AZ USA

[10] QED Therapeut Inc, San Francisco, CA USA

[11] Helsinn Healthcare SA, Lugano, Switzerland

[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.04.107

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-16

引用

页码：S251 / S252

页数：2

共 50 条

[31] Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced cholangiocarcinoma: The AIO-NIFE-trial, an open label, randomized, multicenter phase II trial.
Ettrich, Thomas Jens
Berger, Andreas Wolfgang
Seufferlein, Thomas
Perkhofer, Lukas
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[32] Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial
Jia, Ruinuo
Shan, Tanyou
Zheng, Anping
Zhang, Yaowen
Lu, Ping
Zhang, Guifang
Wang, Feng
Xu, Zhiqiao
Zheng, Guobao
Tang, Dongxia
Zhang, Weiguo
Li, Wanying
Li, Ruonan
Guo, Yibo
Liu, Lina
Luo, Xiaoyong
Zheng, Yingjuan
Chang, Zhiwei
Wang, Qiming
Wang, Xinshuai
Yuan, Xiaozhi
Kong, Guoqiang
Li, Shuoguo
Yang, Ruina
Zhou, Dan
Ren, Jing
Yin, Weijiao
Li, Jingxia
Zhang, Junqian
Wang, Ziqi
Sheng, Manxi
Xu, Bingyi
Li, Liuyan
Liu, Xiaoyi
Lu, Zhihao
Wan, Lixin
Zhou, Fuyou
Gao, Shegan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (20) : 2436 - 2445
[33] A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF301)
Zhang, A.
Boni, V.
Hanson, A.
Mantia, C.
Weickhardt, A.
Yu, E.
Gupta, S.
Robert, M.
Iyer, G.
Millward, M.
Morales-Barrera, R.
Hoimes, C.
Berlin, J.
Mittal, K.
Hill, A.
Racca, F.
Pouessel, D.
Lihou, C.
Tran, B.
Loriot, Y.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S15 - S16
[34] Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial
Lu, Shun
Chen, Zhiwei
Hu, Chengping
Zhang, Jian
Chen, Yuan
Song, Yong
Zhao, Qiong
Fan, Yun
Wu, Gang
Ma, Zhiyong
Fang, Jian
Yu, Qitao
Liu, Zhe
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (11) : 1743 - 1749
[35] A multicenter, open-label, first-in-human study of TYRA-200 in advanced intrahepatic cholangiocarcinoma and other solid tumors with activating FGFR2 gene alterations (SURF201).
Rodon Ahnert, Jordi
Roychowdhury, Sameek
Ellis, Haley
Blanco, Fernando F.
Burn, Timothy
Davis, Jennifer Michelle
Balcer, Alex
Zalutskaya, Alena
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS646 - TPS646
[36] A phase 2, randomized, open-label, multicenter study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.
Li, Jingjing
Qi, Xu
Wei, Qing
Han, Zhe
Cong, Luo
Zhang, Fabiao
Ying, Jieer
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[37] Neoadjuvant durvalumab plus gemcitabine and cisplatin (D plus GemCis) versus gemcis alone for localized biliary tract cancer (BTC): Results of a randomized, multicenter, open-label, phase II trial (DEBATE)
Yoo, C.
Park, J. O.
Kim, K-P.
Hyung, J.
Ryoo, B-Y.
Hong, J. Y.
Shin, S. H.
Song, T. J.
Oh, D.
Lee, W.
Kwak, B. J.
Lee, J. H.
Hwang, D. W.
ANNALS OF ONCOLOGY, 2023, 34 : S216 - S216
[38] A pilot, open-label phase II study of sorafenib combined with cisplatin plus gemcitabine for the treatment of patients with advanced renal collecting duct carcinoma
Shang, Xi Nan
Cui, Chuan Liang
Chi, Zhihong
Si, Lu
Li, Si Ming
Mao, Li Li
Lian, Bin
Tang, Bi Xia
Wang, Xuan
Kong, Yan
Xie, Xiaodong
Zhou, Fang-Jian
Yuan, Jian-Iln
Wei, Qiang
Guo, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[39] Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial.
Zhang, Li
Yu, Gengsheng
Jia, Jun
Peng, Peijian
Lin, Qing
Xi, Xuping
Peng, Jiewen
Xu, Mingjun
Chen, Dongping
Lu, Xiaojun
Wang, Rensheng
Cao, Xiaolong
Chen, Xiaozhong
Lin, Zhixiong
Xiong, Jian Ping
Lin, Qin
Xie, Conghua
Li, Zhihua
Zhao, Chong
Hong, Shaodong
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[40] The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC)
Pascal, Hammel
Jill, Lacy
Fabienne, Portales
Alberto, Sobrero
Beatriz, Garca-Paredes
Edward, Kim
Fernando, Rivera
Jose Luis, Manzano
Eric, Terrebonne
Venu, Bathini
Scot, Dowden
Jamil, Asselah
Jack, Shiansong Li
Thomas, Nydam
Louis, Kayitalire
Philip, Philip
ANNALS OF ONCOLOGY, 2016, 27 : 78 - 79

← 1 2 3 4 5 →